NEW YORK (TheStreet) -- It was Two-For-Tuesday in health care this week as EnteroMedics (ETRM) and OncoMed Pharmaceuticals (OMED) soared. At the peak, OncoMed generated all-time highs, reaching above 120% gains before closing with a gain of 98%. EnteroMedics closed right at the highs of the day, up an impressive 63%.
EnteroMedic investors quickly reversed their skepticism after less-than-stellar third-quarter earnings reported in October upon favorable data from its Maestro system obesity study.
Can investors capture greater gains or is now the time to ring the register?
EnteroMedic is an 11-year-old medical device development company that hasn't generated revenue, much less a profit. In October, the company reported the Maestro device demonstrated benefits in three studies. That news, not totally unlike Tuesday's press release, also rocketed shares over 30%.
Maestro system is a device implanted into obese patients that stimulates the vegus nerve between the esophagus and the stomach, lowering hunger sensations. The system is already approved in Europe and Australia and awaits approval in the U.S. A target market is patients with type II diabetes.Considering the market's currently available and cautiously optimistic outlook for Food and Drug Administration approval, EnteroMedic appears to be a strong buy into a dip. Delivering a favorable study is one thing but it isn't a substitute for revenue and profits.
The likely market reaction is within a few days the stock will settle lower, setting up a more favorable buying opportunity.
For EnteroMedic, however, option trading volume is so light that the lack of liquidity makes the bid/ask spread too wide for all but the most aggressive type of trades. Chasing the price higher doesn't appear to offer a favorable risk-reward because of dilution fear. The chart above demonstrates a six-fold increase in shares outstanding during the past two years while the annual cash burn rate is near the amount of cash on hand. In the last quarter's conference, the company reported a burn rate of $14.1 million for the first nine months ending Sept. 30.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV